Established in: 1978
Managing Director: Kiran Mazumdar-Shaw
Biocon Limited is an Indian biopharmaceutical company headquartered in Bengaluru and Bridgewater, New Jersey, in the U.S. The company was established in 1978 by Kiran Mazumdar-Shaw and manufactures generic active pharmaceutical ingredients sold in over 120 countries.
The company is involved in manufacturing novel biologics, biosimilar insulins and antibodies that are sold in India. Biocon’s formulations include metabolics, oncology, immunotherapy, and nephrology products.
Biocon Limited launched its IPO and went public in March 2004. The company raised ₹315 crore by issuing shares at ₹315 per share. The company is listed on both Indian stock exchanges, BSE and NSE.
History of Biocon Limited
Biocon Limited was founded in 1978 by Kiran Mazumdar and became the first indian company to manufacture and export enzymes to the US and European countries. In 1989, Biocon Biochemicals was acquired by Unilever and merged with its subsidiary, Quest International.
In 1998, Unilever sold its shareholdings to the Indian promoters, making Biocon an independent company. In the following years, the company became the first Indian company to get approved by the USFDA for manufacturing lovastatin. The company became an internationally acclaimed and recognised biopharmaceutical producer.
Business Segments of Biocon Limited
The following are the business segments of Biocon Limited.
-
Biosimilars
Biocon Biologics is the company’s largest revenue driver and is involved in developing, manufacturing and commercialising various biosimilar insulins, monoclonal antibodies and conjugated recombinant proteins for diabetology, oncology, immunology and ophthalmology.
-
Generics
This sector focuses on developing, manufacturing, and supplying affordable Active Pharmaceutical Ingredients and generic formulations. The company’s portfolio includes various chronic therapeutic areas, such as cardiovascular, antidiabetic, and immunosuppressive.
-
Research Services
The research services are offered through the company’s subsidiary, Syngene, which is a Contract Research and Development Organisation (CDMO). This segment provides integrated discovery, development and manufacturing services to pharmaceutical, biotechnology and agrochemical companies worldwide.
-
Novel Bilogics
The company also specialises in discovering and developing innovative, cutting-edge drugs to fulfil the medical needs in autoimmune diseases and cancer.
Subsidiary of Biocon Limited
The following are the subsidiaries of Biocon Limited.
-
Biocon Biologics
Biocon Bilogics is an international biopharmaceutical company that specialises in making life-changing therapies more affordable and accessible globally. This company engages in research, development, manufacturing, and selling of biosimilars, which are highly cost-effective alternatives to expensive biologic drugs used to treat chronic conditions.
-
Syngene International Ltd
Syngene International Limited engages in accelerating drug discovery and manufacturing for global pharmaceutical, biotechnology, nutrition and agrochemical companies. It offers end-to-end services from research and development to production.
-
Clinigene
Clinigene is an international services platform that offers access to life-saving medicines to patients. The company handles the entire drug cycle, manages clinical trials, early access programs and the distribution of licensed and unlicensed medication globally.
-
BBPL
Biocon Biopharmaceuticals Pvt. Ltd. (BBPL) initially was a joint venture with the Cuban Institute CIMAB to develop monoclonal antibodies (MAbs) and cancer vaccines. Later, the company became a wholly owned subsidiary which specialised in providing manufacturing support to Biocon’s biological programs.
-
Biocon-AxiCorp
The company specialises in commercialising Biocon’s biosimilar insulins and generic pharmaceuticals in German and European markets.
-
NeoBiocon
This company is a joint venture subsidiary based in Dubai and oversees the markets and distribution of affordable pharmaceuticals and biopharmaceutical products in the GCC regions.
-
Biofusion Therapeutics Limited
Biofusion Therapeutics Limited is a wholly owned subsidiary which specialises in researching and developing novel molecules for immuno-oncology therapies. It focuses on designing dual-action biologics that accelerate the immune cell activity within the tumour microenvironment to offer long-lasting and durable anti-tumour efficacy.
Biocon Financial Highlights
- Revenue: Biocon reported revenue of ₹17,269.50 crore in FY26 vs ₹16,469.90 crore in FY25. It showed an increase of 4.85% on a yearly basis.
- Operating Profit: Biocon reported an operating profit of ₹447.90 crore in FY26 vs ₹1,886.60 crore in FY25. It showed a decrease of 76.26% on a year-on-year basis.
- Net Profit: Biocon reported a net profit of ₹368.80 crore in FY26 vs ₹1,429.40 crore in FY25. It showed a decrease of 74.20% on a yearly basis.
Biocon Quarterly Result Highlights
- Biocon reported revenue of ₹4,390.50 crore in Jun 2026, compared with ₹4,569.10 crore in Mar 2026, representing a decrease of 3.91% on a quarter-on-quarter (QoQ) basis.
- Biocon reported an operating profit of ₹127.60 crore in Jun 2026, compared with ₹247.50 crore in Mar 2026, representing a decrease of 48.44% on a quarter-on-quarter (QoQ) basis.
- Biocon reported a profit of ₹136.80 crore in Jun 2026, compared with ₹198.60 crore in Mar 2026, reflecting a decrease of 31.12% on a QoQ basis.
- The earnings per share (EPS) of Biocon stood at ₹2.82 during Jun 2026.
Data Source: BSE, Company announcements
Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.
